<DOC>
	<DOC>NCT00002370</DOC>
	<brief_summary>To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety data in patients with advanced HIV disease.</brief_summary>
	<brief_title>Study of Itraconazole in Patients With Advanced HIV Infection</brief_title>
	<detailed_description>Patients will receive intravenous itraconazole solution twice daily for 2 days and then once daily for five additional days. Patients then randomized to receive twice-daily or once-daily itraconazole oral solution for an additional 28 days.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral therapy providing patient has already been on a stable, unchanged regimen for 8 weeks prior to study entry. Patients must have: Documented HIV infection. CD4 lymphocyte count &lt; 300 cells/mm3. No clinically significant abnormalities, elicited by history and physical examination. No clinically significant abnormalities in blood count, biochemical profile, or urinalysis within 2 weeks of study entry. Negative urine screening. No clinically significant abnormalities of electrocardiogram. Prior Medication: Allowed: Antiretroviral therapy providing patient has been on a stable, unchanged regimen for 8 weeks prior to study entry. Exclusion Criteria Coexisting Condition: Patients with the following symptoms and conditions are excluded: Acute opportunistic infection or other significant concurrent illness that would preclude participation for the required 36 days. Unable to swallow oral solution. Obesity greater than 25% of ideal body weight. Concurrent Medication: Excluded: Rifampin. Rifabutin. Phenobarbital. Phenytoin. Carbamazepine. Digoxin. Warfarin. Midazolam. Triazolam. Terfenadine. Astemizole. Cisapride. H2 blockers. Omeprazole. Continual antacids. Didanosine. Any medication known to affect absorption, metabolism or excretion of imidazole or azole compounds. Patients with the following prior symptoms and conditions are excluded: Previous hypersensitivity to azole antifungals. History of surgical procedure that may interfere with absorption of itraconazole. History of significant blood loss in the previous 30 days. Prior Medication: Excluded: Excluded within 15 days prior to study entry: Rifampin. Rifabutin. Phenobarbital. Phenytoin. Carbamazepine. Digoxin. Warfarin. Midazolam. Triazolam. Excluded within 8 weeks prior to study entry: Change in antiretroviral therapy. Risk Behavior: Excluded: Patients who chew tobacco or regularly smoke more than 10 cigarettes per day.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>Administration, Oral</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Drug Administration Schedule</keyword>
</DOC>